Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA2 | P00918 | 5/20 | 0.50 |
| ▸ | PTGS2 | P35354 | 12/20 | 0.44 |
| ▸ | PTGS1 | P23219 | 12/20 | 0.44 |
| ▸ | CA1 | P00915 | 1/20 | 0.37 |
| ▸ | SLC22A12 | Q96S37 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28457565 | 0.73 | PTGS1 (0.61) | PTGS2PTGS1SLC22A12 | |
| SCHEMBL9502701 | 0.73 | HSP90AA1 (0.51) | CA2PTGS2PTGS1CA1 | |
| SCHEMBL9177848 | 0.72 | PTGS2 (0.44) | PTGS2 | |
| SCHEMBL9501613 | 0.72 | HSP90AA1 (0.53) | CA2PTGS2PTGS1CA1 | |
| SCHEMBL29195988 | 0.72 | HSD17B10 (0.40) | CA2PTGS2CA1 | |
| SCHEMBL12054691 | 0.71 | CA2 (0.66) | CA2PTGS2PTGS1CA1 | |
| SCHEMBL10622905 | 0.71 | CA2 (0.61) | CA2PTGS2PTGS1CA1SLC22A12 | |
| SCHEMBL9501563 | 0.71 | MRGPRX1 (0.49) | CA2PTGS2PTGS1SLC22A12 | |
| SCHEMBL16538148 | 0.69 | CA2 (0.64) | CA2PTGS2PTGS1CA1SLC22A12 | |
| SCHEMBL9183407 | 0.69 | CA2 (0.59) | CA2PTGS2PTGS1CA1SLC22A12 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10172856-B2 | 2,4-diaminopyrimidine derivatives as histamine H4 modulators | JANSSEN PHARMACEUTICA NV (BE) | 2019-01-08 | — | — | US | disclosed |
| WO-2018187652-A1 | 2,4-DIAMINOPYRIMIDINE DERIVATIVES AS HISTAMINE H4 MODULATORS | JANSSEN PHARMACEUTICA NV (BE) | 2018-10-11 | — | — | WO | disclosed |
| US-20180289706-A1 | 2,4-DIAMINOPYRIMIDINE DERIVATIVES AS HISTAMINE H4 MODULATORS | JANSSEN PHARMACEUTICA NV (BE) | 2018-10-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10172856-B2 | 2,4-diaminopyrimidine derivatives as histamine H4 modulators | HRH4, HRH3, HRH2 | CA2 1033/4885PTGS2 975/4885PTGS1 1457/4885 |
| US-20180289706-A1 | 2,4-DIAMINOPYRIMIDINE DERIVATIVES AS HISTAMINE H4 MODULATORS | HRH4, HRH3, HRH2 | CA2 1033/4885PTGS2 975/4885PTGS1 1457/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.